About Atelerix
Atelerix is a company based in Newcastle Upon Tyne (United Kingdom) founded in 2017 by Steve Swioklo. It operates as a Product-as-a-Service and Direct-to-Consumer (D2C). Atelerix has raised $2.43 million across 8 funding rounds from investors including Gov.uk, Newable and Oxford Technology. The company has 9 employees as of June 30, 2022. Atelerix offers products and services including Hypothermic Hydrogel Preservation, Leukapheresis Material Preservation, and Primary Tissue Preservation. Atelerix operates in a competitive market with competitors including Brooks Automation, Bridge to Life, Hemanext, Cellbox Solutions and Cold Chain Technologies, among others.
- Headquarter Newcastle Upon Tyne, United Kingdom
- Employees 9 as on 30 Jun, 2022
- Founders Steve Swioklo
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Atelerix Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.43 M (USD)
in 8 rounds
-
Latest Funding Round
$935.51 K (USD), Seed
Jan 28, 2025
-
Investors
Gov.uk
& 7 more
-
Employee Count
9
as on Jun 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Atelerix
Atelerix offers a comprehensive portfolio of products and services, including Hypothermic Hydrogel Preservation, Leukapheresis Material Preservation, and Primary Tissue Preservation.
Cells and tissues are preserved using hypothermic hydrogel technology.
Leukapheresis materials are preserved for research and medical use.
Primary tissues are maintained fresh without cryogenic freezing methods.
People of Atelerix
Unlock access to complete
Unlock access to complete
Funding Insights of Atelerix
Atelerix has successfully raised a total of $2.43M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $935.51 thousand completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Seed — $935,513
-
First Round
First Round
(01 Jun 2017)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Seed - Atelerix | Valuation |
investors |
|
| Jan, 2023 | Amount | Seed - Atelerix | Valuation | Mandashi |
|
| Feb, 2022 | Amount | Grant - Atelerix | Valuation |
investors |
Investors in Atelerix
Atelerix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Newable and Oxford Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on angel investments
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Early-stage innovations are funded by UKI2S across key sectors.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Atelerix
Financial Statements - Atelerix
Atelerix Comparisons
Competitors of Atelerix
Atelerix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brooks Automation, Bridge to Life, Hemanext, Cellbox Solutions and Cold Chain Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vacuum robots for semiconductor wafer handling are developed.
|
|
| domain | founded_year | HQ Location |
Cold storage solutions for organ transplant preservation are provided.
|
|
| domain | founded_year | HQ Location |
Technologies for blood and product storage are developed.
|
|
| domain | founded_year | HQ Location |
Portable devices for cell storage and transport are provided.
|
|
| domain | founded_year | HQ Location |
Thermal packaging solutions and cold chain monitoring services are provided.
|
Frequently Asked Questions about Atelerix
Atelerix was founded in 2017.
Atelerix is headquartered in Newcastle Upon Tyne, United Kingdom.
Mick McLean is the current CEO of Atelerix.
Atelerix is a funded company, having raised a total of $2.43M across 8 funding rounds to date. The company's 1st funding round was a Grant of $576.58K, raised on Jun 01, 2017.
As of Jun 30, 2022, the latest employee count at Atelerix is 9.
Atelerix Ltd is engaged in the development of hypothermic hydrogel-based technology for the preservation of live cells, tissues, and viruses at room temperature. The company operates within the biotechnology sector, offering sustainable and cost-effective solutions for biological transport. Their products cater to various applications, including leukapheresis material, primary tissues, organoids, and microtissues. Emphasis is placed on eco-friendly practices, utilizing natural biopolymers and animal-free materials to reduce carbon footprints in logistics.
Atelerix's top competitors include Brooks Automation, Hemanext and Bridge to Life.
Atelerix offers Hypothermic Hydrogel Preservation, Leukapheresis Material Preservation, and Primary Tissue Preservation.
Atelerix has 8 investors. Key investors include Gov.uk, Newable, Oxford Technology, ACF Investors, and o2h ventures.